The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G03 | Sex hormones and modulators of the genital system | |
| 3 | G03A | Hormonal contraceptives for systemic use | |
| 4 | G03AC | Progestogens | |
| 5 | G03AC08 | Etonogestrel |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 67 ug |
| Active Ingredient | Description | |
|---|---|---|
| Etonogestrel |
Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in OCs. It is structurally derived from 19-nortestosterone and binds with high affinity to progesterone receptors in the target organs. The contraceptive effect of etonogestrel is primarily achieved by inhibition of ovulation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| IMPLANON NXT Implant for subdermal use | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| NEXPLANON Implant | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
